OR WAIT 15 SECS
In replacing the retiring Paul Hegwood, Ricci Whitlow will oversee global clinical trial operations.
Ricci Whitlow has been named as president, clinical supply services for Catalent, succeeding Paul Hegwood, who plans to retire in March 2020 after nearly 45 years in operations, business development, and engineering roles. Whitlow will have global responsibility for Catalent’s clinical supply business, which generated $321.4 million in revenue in fiscal year 2019,the company reported in a Jan. 29, 2020 press statement.
The company’s clinical supply network includes nine cGMP-certified clinical packaging, storage, and distribution facilities in North America, Europe, and Asia, and more 50 depots around the world for clinical storage, distribution, expiry update and relabeling services, and clinical returns management.
Whitlow has more than 25 years’ experience in commercial, operations, and general management roles within the pharmaceutical biologics and medical device industry; and she previously worked for Catalent as vice-president operations, overseeing nine manufacturing facilities in North and South America. She holds a Master’s degree in business administration from the TRIUM program of NYU Stern School of Business, London School of Economics, and HEC Paris; as well as a bachelor of science degree in industrial engineering from Texas A&M University. She is also a certified Six Sigma green belt.
Whitlow will report to Alessandro Maselli, the company’s president and chief operating officer.